Skin and blood markers to predict gestational diabetes and large babies
Compares new sugar-damage markers with HbA1c in pregnant women for predicting gestational diabetes.
Key facts
- Who runs it
- University Hospital, Bordeaux
- Where
- France1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- New Markers of Glycation to Predict Gestational Diabetes Mellitus and Macrosomia.
- Status
- Recruiting
- People taking part
- 800 people, planned
- Started
- 18 Dec 2023
- Expected to end
- Sept 2028
- Type of study
- Interventional
- Treatments tested
- Pregnant women
- Record updated
- 15 January 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for pregnant women, with or without risk factors for diabetes in pregnancy, before 28 weeks of pregnancy. It tests blood and skin markers of sugar damage to predict diabetes in pregnancy and a large baby.
- Age
- 18 years to 99 years
- Sex
- Pregnant women
- Disease stage
- Pregnancy with one baby, at less than 28 weeks since the last period. A twin pregnancy reduced to one baby before 14 weeks can also join.
- Earlier treatment
- People who had weight-loss (bariatric) surgery cannot join.
Main reasons for not taking part
- 28 weeks of pregnancy or more
- Pregnancy with more than one baby
- Diabetes known before the pregnancy
- Past weight-loss (bariatric) surgery
- Planned birth in a maternity unit not taking part in the study
This trial only enrols pregnant participants. The registry sentence this rests on: Singleton pregnancy (or twin pregnancy reduced spontaneously or medically before 14 weeks of amenorrhea)
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Age ≥ 18 years
- Singleton pregnancy (or twin pregnancy reduced spontaneously or medically before 14 weeks of amenorrhea)
- Gestational age at inclusion <28 weeks of amenorrhea
- Participant affiliated with or beneficiary of a social security scheme
- Collection of patient consent
Who cannot take part
- Known diabetes prior to pregnancy
- History of bariatric surgery
- Gestational age at inclusion ≥ 28 weeks of amenorrhea
- Multiple pregnancy
- Expected delivery in another maternity unit not participating in the study
- Person deprived of liberty by judicial or administrative decision
- Guardianship or curatorship
- Participant not affiliated or not benefiting from a social security scheme
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 99 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Gestational diabetes mellitus (GDM) increases the risk of macrosomia and other adverse pregnancy outcomes. Screening strategies are debated: universal vs. selective, and macrosomia may begin before the time of screening, suggesting that glycation markers may have an interest. The objective of this trail is to compare novel markers: skin autofluorescence and glycated albumin, to HbA1c (reference) as predictors of GDM, macrosomia and other adverse outcomes, in pregnant women.
The group in the trial
- Pregnant womenTreatment being tested
Pregnant women, with gestational age at inclusion \<28 weeks of amenorrhea, with or without risk factors for GDM will be included in the first consultation at the Maternity Hospital (Bordeaux University Hospital). Determination of glycation markers (HbA1c, glycated albumin, and skin autofluorescence).
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- New Markers of Glycation to Predict Gestational Diabetes Mellitus and Macrosomia.
- Plain-language title
- Skin and blood markers to predict gestational diabetes and large babiesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Criteria questions
- Built from NCT06048510, who can take part
- Record updated
- 15 January 2026